Shareholder Alert: Robbins LLP Announces AnaptysBio, Inc. (ANAB) Sued for Misleading Shareholders

Editorial & Advertiser Disclosure Global Banking And Finance Review is an independent publisher which offers News, information, Analysis, Opinion, Press Releases, Reviews, Research reports covering various economies, industries, products, services and companies. The content available on is sourced by a mixture of different methods which is not limited to content produced and supplied by various staff writers, journalists, freelancers, individuals, organizations, companies, PR agencies Sponsored Posts etc. The information available on this website is purely for educational and informational purposes only. We cannot guarantee the accuracy or applicability of any of the information provided at with respect to your individual or personal circumstances. Please seek professional advice from a qualified professional before making any financial decisions. also links to various third party websites and we cannot guarantee the accuracy or applicability of the information provided by third party websites. Links from various articles on our site to third party websites are a mixture of non-sponsored links and sponsored links. Only a very small fraction of the links which point to external websites are affiliate links. Some of the links which you may click on our website may link to various products and services from our partners who may compensate us if you buy a service or product or fill a form or install an app. This will not incur additional cost to you. A very few articles on our website are sponsored posts or paid advertorials. These are marked as sponsored posts at the bottom of each post. For avoidance of any doubts and to make it easier for you to differentiate sponsored or non-sponsored articles or links, you may consider all articles on our site or all links to external websites as sponsored . Please note that some of the services or products which we talk about carry a high level of risk and may not be suitable for everyone. These may be complex services or products and we request the readers to consider this purely from an educational standpoint. The information provided on this website is general in nature. Global Banking & Finance Review expressly disclaims any liability without any limitation which may arise directly or indirectly from the use of such information.

Shareholder rights law firm Robbins LLP announces that a purchaser of AnaptysBio, Inc. (NASDAQ: ANAB) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between October 10, 2017 and November 7, 2019. AnaptysBio is a clinical stage biotechnology company that engages in developing antibody product candidates focused on unmet medical needs in inflammation. AnaptysBio’s lead drug candidate is etokimab, which treats various inflammatory diseases.

If you suffered a loss as a result of AnaptysBio’s misconduct, click here.

AnaptysBio, Inc. (ANAB) Accused of Misleading Shareholders

According to the complaint, in October 2017, AnaptysBio touted “positive” data from its phase 2a clinical trial of etokimab, stating it provided “a solid foundation for the continued development of [etokimab] across a number of atopic diseases” and that the drug’s efficacy was “very encourag[ing].” However, on March 26, 2018, RBC Capital Markets issued a report questioning the veracity of AnaptysBio’s interim analysis of its Phase 2a trial. On April 4, 2018, RBC Capital Markets reduced its price target on the Company’s stock and highlighted “concern surrounding management credibility.” The legitimacy of etokimab’s efficacy in the treatment of inflammatory diseases came into question again on June 21, 2019, when Credit Suisse issued a report doubting the veracity of the Company’s Phase 2a atopic dermatitis data, citing AnaptysBio’s small sample size and failure to provide critical details. Finally, on November 8, 2019, AnaptysBio announced disappointing data from its Phase 2b study that revealed that etokimab “failed to meet the primary endpoint of the trial.” On this news, several analysts downgraded the AnaptysBio’s stock and the Company’s share price fell $25.98, a staggering 72%, to close at $10.18 per share.

AnaptysBio, Inc. (ANAB) Shareholders Have Legal Options

Contact us to learn more: Leo Kandinov (800) 350-6003 [email protected] Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.

Leo Kandinov

Robbins LLP

5040 Shoreham Place

San Diego, CA 92122

[email protected]

(619) 525-3990 or Toll Free (800) 350-6003